Evaluation of corneal morphologic and functional parameters after use of topical cyclosporine-a 0.05% in dry eye.
OBJECTIVE
To report the effect of topical Cyclosporine-A (CsA) 0.05% on corneal morphologic and functional parameters in patients with dry eye.


METHODS
In this prospective and observational study 30 eyes of 30 patients who received topical CsA 0.05% for treatment of dry eye were evaluated. Each clinical examination included a routine Schirmer I test and tear film break-up time (TBUT) was performed at baseline and after 1, 2, 3, and 6 months of treatment. All participants also underwent central corneal thickness (CCT) measurements with ultrasound pachymetry, endothelial cell density (ECD) with specular microscopy, corneal topographical evaluation with Orbscan II, and corneal biomechanical parameters with Ocular Response Analyzer measurements at baseline and after treatment.


RESULTS
The Schirmer I test and TBUT were significantly improved after treatment (for both; P<0.01). The CCT, topographical findings, ECD, and corneal biomechanical parameters were not significantly different at baseline and follow-up visits (P>0.05). No serious adverse effects were seen at follow up visits.


CONCLUSIONS
The study showed that Topical CsA 0.05% caused no changes on corneal morphology and function.
Department of Ophthalmology, Kanuni Sultan Suleyman Education and Research Hospital, Istanbul, Turkey. dr.necipkara@gmail.com
Necip
N
Kara
Hasan
H
Altinkaynak
Yasin
Y
Goker
Kemal
K
Yuksel
Yusuf
Y
Yildirim
D060433:Administration, Ophthalmic; D000328:Adult; D003315:Cornea / Q000187:drug effects* / Q000473:pathology; D063171:Corneal Pachymetry; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000473:pathology; D004728:Endothelium, Corneal / Q000187:drug effects / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013666:Tears / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D016572:Cyclosporine